Jagdeesh Ullal
Overview
Explore the profile of Jagdeesh Ullal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hirsch I, Draznin B, Buse J, Raghinaru D, Spanbauer C, Umpierrez G, et al.
Diabetes Care
. 2024 Nov;
48(1):118-124.
PMID: 39571106
Objective: To evaluate whether continuous glucose monitoring (CGM) could assist providers in intensifying glycemic management in hospitalized patients with type 2 diabetes. Research Design And Methods: At six academic hospitals,...
2.
Ohori N, Cuda J, Bastacky S, Yip L, Karslioglu-French E, Morariu E, et al.
Cancer Cytopathol
. 2023 Oct;
132(2):109-118.
PMID: 37849056
Background: Indeterminate thyroid cytopathology diagnoses represent differing degrees of risk that are corroborated by follow-up studies. However, traditional cytologic-histologic correlation may overestimate the risk of malignancy (ROM) because only a...
3.
Ullal J, Kutney K, Williams K, Weber D
J Clin Transl Endocrinol
. 2022 Jan;
27:100291.
PMID: 35059303
The advent of highly effective CFTR modulator therapies has slowed the progression of pulmonary complications in people with cystic fibrosis. There is increased interest in cystic fibrosis bone disease (CFBD)...
4.
Sherwood J, Ullal J, Kutney K, Hughan K
J Clin Transl Endocrinol
. 2022 Jan;
27:100283.
PMID: 35024343
Cystic fibrosis-liver disease (CFLD) is one of the most common non-pulmonary complications in the CF population, is associated with significant morbidity and represents the third leading cause of mortality in...
5.
Oxman R, Roe A, Ullal J, Putman M
J Clin Transl Endocrinol
. 2022 Jan;
27:100289.
PMID: 34984172
As cystic fibrosis transmembrane regulator (CFTR) modulator therapies offer greater longevity and improved health quality, women living with cystic fibrosis (CF) are increasingly pursuing pregnancy. Maternal risks for pregnant women...
6.
Ullal J, Dignan C, Cwik R, McFarland R, Gaines M, Aloi J
J Diabetes Sci Technol
. 2020 Aug;
15(2):523-524.
PMID: 32814453
No abstract available.
7.
Ullal J, Aloi J
Curr Diab Rep
. 2019 Nov;
19(11):120.
PMID: 31686274
Purpose Of Review: The goal of this review is to summarize information about insulin dosing software and calculators used as computerized decision support systems or electronic glucose management systems (eGMS)....
8.
Ullal J, Aloi J, Reyes-Umpierrez D, Pasquel F, McFarland R, Rabinovich M, et al.
J Diabetes Sci Technol
. 2018 Jan;
12(1):39-46.
PMID: 29291648
Background: This study was performed to investigate the efficacy of Glucommander (GM) (Glytec®), a computer-based algorithm versus standard (paper form-based) continuous insulin infusion (CII) in the treatment of patients with...
9.
Aloi J, Bode B, Ullal J, Chidester P, McFarland R, Bedingfield A, et al.
J Diabetes Sci Technol
. 2016 Aug;
11(1):12-16.
PMID: 27555601
Background: American Diabetes Association (ADA) guidelines recommend a basal bolus correction insulin regimen as the preferred method of treatment for non-critically ill hospitalized patients. However, achieving ADA glucose targets safely,...
10.
Ullal J, McFarland R, Bachand M, Aloi J
Diabetes Technol Ther
. 2016 Jan;
18(2):100-3.
PMID: 26783996
Background: Efforts at improving quality metrics in diabetes focus on minimizing adverse events and avoiding re-admissions to the hospital. Our experience with Glucommander™ (Glytec, Greenville, SC), a cloud-based insulin management...